Trazodone Teva

Quick links to important sections

Trazodone Teva

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trazodone Teva

Property Description
Active ingredient Trazodone Hydrochloride
Form Tablet (Immediate-release & Modified-release)
Pharmacological class Atypical Antidepressant; Serotonin Antagonist and Reuptake Inhibitor (SARI)
Common use Modulation of mood regulation and supporting neural equilibrium
Origin Synthetic Triazolopyridine derivative

What Pharmacological Class Does Trazodone Teva Belong To?

Trazodone Teva is a prescription-only synthetic medication containing the active substance Trazodone Hydrochloride, which is classified as an Atypical Antidepressant. The drug is manufactured by Teva Pharmaceuticals, confirming its origin within a globally recognized pharmaceutical entity.

The drug is a triazolopyridine derivative and falls into the specific pharmacological class known as a Serotonin Antagonist and Reuptake Inhibitor (SARI). The SARI classification reflects Trazodone’s distinctive dual mechanism on the central nervous system. It inhibits the reabsorption of the neurotransmitter serotonin into nerve cells while simultaneously blocking specific serotonin receptors, providing a robust action profile. This combined approach is designed to effectively modulate central nervous system signaling.

Trazodone Teva Tablet Forms and Overall Purpose

Trazodone Teva is prepared exclusively for oral administration in the form of a tablet, with versions available as both immediate-release and modified-release formulations.

As a medication designed for systemic action, the overall purpose of Trazodone Teva is to modulate and support equilibrium within the brain's chemical messaging pathways. Trazodone is an agent used to stabilize and regulate mood disturbances and related symptoms. The substance's core pharmacological role involves facilitating the stabilization of mood regulation and providing generalized supportive effects for adults experiencing imbalances in neural communication. The availability of the modified-release tablet is a key differentiating feature, allowing for therapeutic flexibility in managing the drug's sustained effects over time.

Regulatory References

  1. MedlinePlus Drug Information
  2. National Institutes of Health (NIH)
  3. NIH Trazodone Information
  4. Serotonin Antagonist and Reuptake Inhibitor (SARI)

What side effects are possible with Trazodone Teva?

The safety profile of Trazodone Teva is characterized by adverse reactions formally documented by governmental regulatory authorities (EMA SmPC, FDA DailyMed). These events are classified by frequency and grouped into System-Organ Classes (SOCs).

Adverse Reaction Scope

Classification Examples of Officially Listed Reactions
Very Common Drowsiness, dizziness, dry mouth, headache, sedation, nausea.
Common Blurred vision, confusion, constipation, vomiting, orthostatic hypotension, tremor.
Rare Priapism (painful, prolonged erection), blood dyscrasias, hepatic function disorder, seizures.
System-Organ Classes Nervous System, Gastrointestinal, Vascular, Cardiac, Reproductive System, and Blood and Lymphatic System Disorders.

Serious Adverse Reactions and Safety Patterns

The regulatory label highlights several clinically significant, though less frequent, adverse reactions. These include the documented risk of Serotonin Syndrome, Torsades de Pointes (a type of cardiac arrhythmia) and other cardiac abnormalities, and Priapism, which may require medical intervention.

A significant regulatory warning notes the risk of Suicidal Thoughts and Behaviors, particularly at the start of treatment and following dose changes, especially in young adults. This risk warrants close observation during the initial months of therapy. The common effects of sedation and orthostatic hypotension are officially noted as being more frequent at the initiation of treatment.

Safety Constraints and Special Populations

Official labeling defines specific restrictions, including that Trazodone Teva is contraindicated in individuals recovering from a recent myocardial infarction (MI) or when used concomitantly with Monoamine Oxidase Inhibitors (MAOIs). Cautions are noted for special populations: Older Adults may be more susceptible to sedative effects and orthostatic hypotension. Caution is also advised in patients with existing hepatic or renal impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes overdose with Trazodone Hydrochloride as potentially ranging from mild to life-threatening, requiring immediate medical attention in all cases. Suspected overdose must be reported to emergency services immediately.

Documented Overdose Manifestations

System Official Regulatory Findings
Central Nervous System Drowsiness, confusion, disorientation, dizziness, seizures, and coma.
Cardiovascular System Hypotension (low blood pressure), tachycardia, cardiac arrhythmias, QT prolongation, and Torsade de pointes.
Other Specific Events Nausea, vomiting, and priapism (a prolonged, painful erection) are documented.

Required Emergency Actions

The most serious outcomes—including respiratory arrest, severe cardiac conduction abnormalities, and Serotonin Syndrome—are particularly noted when Trazodone is co-ingested with alcohol or other central nervous system depressants. Regulatory documents state that no specific antidote is known for Trazodone overdose.

Management in a hospital setting focuses on providing symptomatic and supportive treatment, with continuous cardiac monitoring necessary due to the risk of arrhythmias. Intervention with activated charcoal or gastric lavage may be considered in early stages.

Therapeutic Uses of Trazodone Teva

Trazodone Teva is applied across domains where additional symptomatic support is needed, supporting patients during episodes of heightened discomfort and helping to manage distressing symptoms. The primary therapeutic focus is the treatment of Major Depressive Disorder (MDD).

The medication is commonly used to help with managing core depressive symptoms like low mood and loss of interest; co-occurring symptoms of anxiety and inner tension; and associated sleep disturbances (insomnia). It plays a role in managing symptoms that may become intense or disruptive, providing supportive relief when symptoms interfere with routine activities.

“Trazodone Teva is commonly used to support patients in managing symptom fluctuations and contribute to a sense of stability when symptoms are more noticeable.”

This medication is relevant in clinical settings marked by heightened emotional distress, offering support that helps ease the overall symptom burden.

Quick Fact: Relief for Insomnia
Supports the management of sleep disturbances by easing difficulties in falling asleep and managing interrupted sleep.

The application of Trazodone Teva assists with maintaining functional stability during episodes where symptoms intensify temporarily.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Trazodone Teva (Trazodone Hydrochloride) is officially indicated for use in adults. Eligibility for the medicine is strictly defined by regulatory documents, outlining groups who must avoid its use and those who require significant caution.


Contraindications and Restrictions

Classification Population/Condition
Absolute Contraindication Patients with known hypersensitivity to Trazodone or any ingredient.
Absolute Contraindication Use with or within 14 days of discontinuing a Monoamine Oxidase Inhibitor (MAOI).
Use Not Recommended Patients in the initial recovery phase of a myocardial infarction (recent heart attack).

Age and Organ Function Limits

  • Pediatric Use: The drug is not approved for patients under 18 years of age because safety and effectiveness have not been established in this population.
  • Older Adults (Geriatric): Use is permitted, but caution and close monitoring are specifically required due to increased potential for side effects like orthostatic hypotension and hyponatremia.
  • Organ Impairment: Caution is mandatory for patients with renal impairment (kidney problems) or hepatic impairment (liver problems), as the drug has not been adequately studied in these populations.

Specific Caution Required

Caution is also specified for patients with pre-existing cardiac disease, risk factors for a prolonged QT interval, and specific conditions that predispose to priapism or angle-closure glaucoma.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Co-administration of Trazodone Teva with other medicines and products requires careful management due to potential alterations in drug levels or combined pharmacological effects, as documented in official regulatory labeling.

Pharmacokinetic Interactions (Drug Levels)

Trazodone is metabolized by the CYP3A4 enzyme. Concomitant use with strong CYP3A4 inhibitors (e.g., Ritonavir, Ketoconazole) significantly increases Trazodone exposure, necessitating consideration for a reduced dose. Conversely, co-administration with strong CYP3A4 inducers (e.g., Carbamazepine) substantially decreases Trazodone exposure, which may require an increased dose based on clinical response.

Pharmacodynamic Interactions (Combined Effects)

Monoamine Oxidase Inhibitors (MAOIs) are contraindicated with Trazodone Teva due to the high risk of serotonin syndrome, requiring a 14-day washout period before and after Trazodone therapy. The risk of serotonin syndrome is also increased with other serotonergic agents (e.g., Triptans, SSRIs, SNRIs).

Other clinically significant interactions include additive effects with:

  • CNS Depressants (e.g., alcohol, barbiturates), which can enhance central nervous system depression.
  • Drugs that Prolong the QT Interval, increasing the risk of cardiac arrhythmia.
  • Anticoagulants/Antiplatelets (e.g., Warfarin, NSAIDs), increasing the documented risk of bleeding.

Digoxin and Phenytoin levels may be altered when co-administered with Trazodone, requiring therapeutic drug monitoring.

Mechanism of Action

Trazodone Teva operates through a complex, multi-target mechanism in the central nervous system (CNS) and periphery, classifying its functional profile as a Serotonin Antagonist and Reuptake Inhibitor (SARI). The primary mechanism involves simultaneous antagonism at the 5-HT2A receptor and inhibition of the Serotonin Transporter (SERT). This dual strategy alters the synaptic availability and functional signaling of serotonin (5-HT). By blocking the 5-HT2A receptor, Trazodone redirects increased synaptic serotonin to other receptor subtypes, which influences the activity of neural circuits responsible for regulating monoamine signaling.

Antagonism also occurs at two secondary CNS targets: the Histamine H1 receptor and the alpha1-adrenergic receptor. The combined blocking of the H1 and 5-HT2A receptors suppresses excitatory signaling and arousal-promoting circuits in the CNS, resulting in the suppression of CNS arousal pathways and decreased neural excitability.

The expression of Trazodone's SERT inhibitory action is concentration-dependent, becoming functionally prominent only at higher systemic concentrations. The antagonism of the alpha1-adrenergic receptor also acts on the autonomic system, resulting in alpha1-adrenergic receptor blockade, which alters the regulation of peripheral vascular tone.

Dosage and Administration Information

How to Use Trazodone Teva: Administration Principles

Trazodone Teva, containing Trazodone Hydrochloride, is administered solely via the oral route as a tablet. The specific administration instructions are differentiated by the formulation: immediate-release (IR) or extended-release (ER) tablets.

Dosage and Frequency Regimens

The standard regimen for immediate-release tablets begins with an adult dose of 150 mg per day, typically administered in divided doses. Doses may be increased by 50 mg every three to four days up to a maximum of 400 mg/day for outpatients, or up to 600 mg/day for hospitalized patients.

The extended-release formulation has a distinct regimen, starting at 150 mg taken once daily and generally not exceeding a maximum of 375 mg per day.

Administration Conditions

Formulation Type Timing in Relation to Meals Administration Rule
Immediate-Release (IR) Must be taken shortly after a meal or light snack Typically taken in divided doses; tablets must not be chewed or crushed.
Extended-Release (ER) Must be taken on an empty stomach Taken once daily (usually at bedtime); tablets must not be chewed or crushed.

Usage Duration and Special Populations

Treatment duration often continues for several months after a response is achieved to ensure stability. When concluding therapy, the dose must be gradually reduced rather than stopped abruptly. For older or frail adults, the initial dose is typically reduced to 100 mg per day, with the daily dose generally not exceeding 300 mg.

Recent Clinical Evidence

Recent Clinical Evidence


Efficacy Research Overview

Clinical trials have primarily investigated trazodone's role in treating Major Depressive Disorder (MDD) and insomnia. For MDD, the evidence base includes double-blind, placebo-controlled studies that examined the drug's effect on reducing depressive symptoms, such as depressed mood, loss of interest, and sleep disturbances, compared to an inactive substance. These trials generally assessed symptom changes over periods typically ranging from four to six weeks.

Findings on Use for Insomnia

Further research has explored trazodone’s impact on sleep parameters. In patients with MDD experiencing associated insomnia, studies have investigated changes in sleep continuity (e.g., wakefulness after sleep onset) and total sleep time. Lower doses of the medication, often used off-label for sleep, have been the subject of observational studies, though formal, high-quality evidence supporting this use remains limited.

Summary of Study Results

Outcome Parameter Typical Study Finding Limitations
Depressive Symptoms Reduction in scores on standardized depression scales compared to placebo. Effects are not universal; individual response varies.
Sleep Continuity Increases in total sleep duration and reduction in nocturnal awakenings. Effect is dose-dependent; data mostly drawn from shorter-term trials.

Safety and Tolerability

The most commonly reported adverse events in clinical trials include drowsiness, dizziness, dry mouth, and nausea. Most events are described as mild to moderate in severity. Studies on trazodone's safety profile indicate that postural hypotension (a drop in blood pressure upon standing) is a notable consideration, particularly in older adult populations.

Key Studies & References

  1. The efficacy and safety of trazodone for sleep problems in depressive patients: a GRADE-assessed systematic review and meta-analysis of clinical trials
  2. TRAZODONE HYDROCHLORIDE TABLETS, USP - DailyMed (FDA-mandated Labeling/Clinical Trial Reports)
  3. Trazodone - StatPearls - NCBI Bookshelf (Review of Efficacy, Safety, and Dosing)

Frequently Asked Questions (FAQ)

Common questions about Trazodone Teva (FAQ)


Q: Is Trazodone Teva the same as generic trazodone?

A: Trazodone Teva is the name used by Teva Pharmaceuticals for their version of the active drug, Trazodone Hydrochloride. This product is considered a generic equivalent of the brand-name medication Desyrel®, as defined in official regulatory databases.


Q: What is serotonin syndrome and is it a risk with Trazodone Teva?

A: Serotonin syndrome is a serious condition that may potentially occur when taking Trazodone, especially alongside other serotonergic medicines. Regulatory warnings describe symptoms that may include agitation, confusion, fast or irregular heartbeat, high fever, or severe muscle stiffness.


Q: What is the experience of stopping Trazodone Teva?

A: The official label warns about a discontinuation syndrome that may occur when treatment is stopped. Official guidance emphasizes that the dose should be gradually reduced, rather than stopped suddenly, to help prevent withdrawal symptoms. Commonly reported effects during this time may include dizziness and nausea.


Q: What are the possible interactions between Trazodone Teva and over-the-counter pain relievers?

A: Regulatory warnings state there is an increased risk of bleeding when Trazodone is used with medications that affect blood clotting. This includes nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and aspirin. The official labeling emphasizes caution with these combinations.


Q: Can Trazodone Teva interact with herbal supplements like St. John's Wort?

A: St. John's Wort is classified as a serotonergic agent. Taking Trazodone Teva with other such agents, including herbal supplements like St. John's Wort, may increase the potential risk of developing serotonin syndrome, according to official labeling.


Q: What is priapism, and why is it sometimes mentioned with Trazodone Teva?

A: Priapism is defined by official sources as a prolonged and sometimes painful erection lasting longer than six hours and is not related to sexual activity. The regulatory label lists this as a rare, serious adverse reaction that may warrant immediate medical evaluation.


Q: What are the ingredients in Trazodone Teva tablets besides the main drug?

A: The official product label lists several inactive ingredients, or excipients, used to form the tablet. These include substances like colloidal silicon dioxide, microcrystalline cellulose, and magnesium stearate.


Q: What are the signs of a serious allergic reaction to Trazodone Teva?

A: A serious allergic reaction (anaphylaxis) is rare but possible. Medical information describes signs such as sudden swelling of the lips, mouth, throat, or tongue, rapid breathing, or fainting, as characteristics of a serious allergic reaction.


Q: What are the major organs that process Trazodone Teva in the body?

A: Trazodone is primarily broken down (metabolized) in the liver by a specific enzyme called CYP3A4. Regulatory warnings also advise caution for patients with renal (kidney) impairment, indicating that both the liver and kidneys are involved in its processing and elimination.


Q: What kind of monitoring is typically recommended for people taking Trazodone Teva?

A: Regulatory documents recommend monitoring patients closely for several potential effects. This includes observing for suicidal thoughts and behaviors, especially during the first months of treatment, as well as checking for changes to blood pressure, heart rate, and bleeding risk.


Q: What is the main difference between Trazodone Teva and other medications for depression?

A: Trazodone is classified as a Serotonin Antagonist and Reuptake Inhibitor (SARI). This mechanism is distinct from common classes like Selective Serotonin Reuptake Inhibitors (SSRIs) because Trazodone both blocks specific serotonin receptors and inhibits serotonin reuptake.


Q: Does Trazodone Teva cause weight gain?

A: Some official adverse reaction reports and product information documents note changes in appetite or weight as possible side effects. Certain regulatory labels have listed weight loss as a less common event, and weight gain is not listed as a very common or common side effect on its official label.


Q: How long does it typically take to feel the effects of Trazodone Teva?

A: Studies and official information indicate that the reduction of depressive symptoms is typically assessed over a period of four to six weeks in clinical trials. The time it takes for an individual to feel the intended therapeutic effects can vary.


Q: What happens if I forget to take a dose of Trazodone Teva?

A: Regulatory consumer information advises that if a dose is missed, it should be taken as soon as it is remembered, unless it is almost time for the next scheduled dose. If so, regulatory guidance suggests skipping the missed dose and resuming the regular schedule. Taking two doses at once to compensate for a missed dose is generally advised against.


Q: Are there any major diet restrictions while taking Trazodone Teva?

A: Official labeling explicitly cautions against consuming alcohol and notes an interaction with grapefruit or grapefruit juice due to its effect on the drug's metabolism. Regulatory documents do not list major dietary restrictions for common food groups.


Q: Can Trazodone Teva cause unusual dreams or vivid nightmares?

A: While not listed as a common side effect, some post-marketing reports or descriptions of discontinuation effects include vivid dreams or disturbed sleep.


Q: How long does Trazodone Teva stay in the body?

A: Official pharmacokinetic information indicates that Trazodone has a relatively short half-life, meaning it is quickly processed and eliminated from the body. The rate of elimination can vary depending on the immediate-release or extended-release formulation.


Q: Does Trazodone Teva cause dependence or addiction?

A: Trazodone is not classified as a controlled substance and is generally considered to have a low potential for abuse or addiction. However, the body can develop physical dependence over time, which is why a gradual dose reduction is often necessary when stopping the medicine.


Q: Is Trazodone Teva used for anxiety?

A: Trazodone Teva is officially indicated for the treatment of Major Depressive Disorder (MDD). Its use for conditions such as generalized anxiety is not included in the FDA-approved indications.


Q: Do regulatory agencies classify Trazodone Teva as a controlled substance?

A: No. According to the U.S. Controlled Substances Act, Trazodone is not classified as a controlled substance by regulatory agencies.


Q: How does Trazodone Teva compare to SSRIs in terms of common side effects?

A: Official side effect profiles indicate that Trazodone is often associated with a higher incidence of sedation, dizziness, and orthostatic hypotension (a drop in blood pressure when standing) compared to other classes like SSRIs.


Q: Is Trazodone Teva safe to use during pregnancy or breastfeeding?

A: Regulatory agencies state that data on the use of Trazodone during pregnancy is inconclusive, and its use is typically considered only if the potential benefit is determined to justify the risk. The drug is known to be excreted into human milk, so a decision must be made, in consultation with a healthcare provider, to discontinue either breastfeeding or the medication.


Q: Are there different brand names for Trazodone besides Teva?

A: Yes. Trazodone Hydrochloride is the generic name of the drug. Other brand names exist or have existed in various global markets, such as Desyrel®, Oleptro®, and Desyrel Dividose®.


Q: Does Trazodone Teva have a Black Box Warning?

A: Yes. The FDA has issued a Boxed Warning (often referred to as a Black Box Warning) regarding the increased risk of suicidal thoughts and behaviors. This warning applies particularly to children, adolescents, and young adults when starting treatment or following dose changes.


Q: Can Trazodone Teva interact with grapefruit or grapefruit juice?

A: Yes. Regulatory documents state that Trazodone is metabolized by the CYP3A4 enzyme. Consuming grapefruit or grapefruit juice, which are known strong inhibitors of this enzyme, can significantly increase the level of Trazodone in the body.


Q: Is Trazodone Teva used for chronic pain?

A: Trazodone Teva is officially indicated for the treatment of Major Depressive Disorder (MDD). Its use for conditions such as chronic pain is not included in the FDA-approved indications.


Q: Are there any known issues with taking Trazodone Teva before surgery?

A: Official warnings highlight potential risks such as orthostatic hypotension (low blood pressure upon standing), cardiac arrhythmias, and increased bleeding risk. These factors are generally noted in regulatory warnings as requiring awareness or review prior to any planned surgery.


Q: How is Trazodone Teva related to tricyclic antidepressants?

A: Trazodone is chemically classified as a triazolopyridine derivative, which means it is structurally unrelated to tricyclic antidepressants (TCAs). However, the medicine also has effects on the alpha1-adrenergic receptors, a feature it shares with some TCAs.

How should Trazodone Teva be stored and disposed of?

The storage and disposal of Trazodone Teva tablets must adhere to official regulatory conditions to maintain stability and ensure safety.

Storage Requirements

Trazodone Teva must be stored at Controlled Room Temperature (CRT), which is between 20 C and 25 C (68 F and 77 F). The product must be protected from light, moisture, and excess heat, and should not be stored in high-humidity areas, such as a bathroom.

Tablets must remain in the original container, which must be kept tightly closed and fitted with a child-resistant cap. The medicine must be stored out of the sight and reach of children.


Disposal Instructions

Disposal of unused or expired tablets should ideally occur through an authorized drug take-back program. If this option is unavailable, the medicine must be prepared for disposal in household trash by mixing the tablets with an undesirable substance, such as coffee grounds or dirt, before sealing the mixture in a bag. Trazodone Teva is not on the list of medicines recommended for flushing down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Trazodone Teva found in:

A-Z Index: